Maternal phenylketonuria pregnancy outcome

a preliminary report of facial dysmorphology and major malformations

B. Rouse, Lillian Lockhart, Reuben Matalon, C. Azen, R. Koch, W. Hanley, H. Levy, F. dela Cruz, E. Friedman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

It is clear from the preliminary data that major malformations, i.e. intrauterine growth retardation, microcephaly and cardiac defects, tend to decrease in frequency as the blood phenylalanine level drops, but not enough to suggest that phenylalanine levels of 600 μmol/L are safe levels. The facial dysmorphic features may be used as a sensitive indicator that blood phenylalanine levels should be below 360 μmol/L. It is hoped that at the end of the collaborative study more data will be available to suggest blood phenylalanine levels which will prevent the deleterious effects of maternal PKU syndrome.

Original languageEnglish (US)
Pages (from-to)289-291
Number of pages3
JournalJournal of Inherited Metabolic Disease
Volume13
Issue number3
DOIs
StatePublished - May 1990
Externally publishedYes

Fingerprint

Maternal Phenylketonuria
Pregnancy Outcome
Phenylalanine
Microcephaly
Fetal Growth Retardation

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Endocrinology

Cite this

Maternal phenylketonuria pregnancy outcome : a preliminary report of facial dysmorphology and major malformations. / Rouse, B.; Lockhart, Lillian; Matalon, Reuben; Azen, C.; Koch, R.; Hanley, W.; Levy, H.; dela Cruz, F.; Friedman, E.

In: Journal of Inherited Metabolic Disease, Vol. 13, No. 3, 05.1990, p. 289-291.

Research output: Contribution to journalArticle

Rouse, B. ; Lockhart, Lillian ; Matalon, Reuben ; Azen, C. ; Koch, R. ; Hanley, W. ; Levy, H. ; dela Cruz, F. ; Friedman, E. / Maternal phenylketonuria pregnancy outcome : a preliminary report of facial dysmorphology and major malformations. In: Journal of Inherited Metabolic Disease. 1990 ; Vol. 13, No. 3. pp. 289-291.
@article{49c370188d184413b67cfbb68264931c,
title = "Maternal phenylketonuria pregnancy outcome: a preliminary report of facial dysmorphology and major malformations",
abstract = "It is clear from the preliminary data that major malformations, i.e. intrauterine growth retardation, microcephaly and cardiac defects, tend to decrease in frequency as the blood phenylalanine level drops, but not enough to suggest that phenylalanine levels of 600 μmol/L are safe levels. The facial dysmorphic features may be used as a sensitive indicator that blood phenylalanine levels should be below 360 μmol/L. It is hoped that at the end of the collaborative study more data will be available to suggest blood phenylalanine levels which will prevent the deleterious effects of maternal PKU syndrome.",
author = "B. Rouse and Lillian Lockhart and Reuben Matalon and C. Azen and R. Koch and W. Hanley and H. Levy and {dela Cruz}, F. and E. Friedman",
year = "1990",
month = "5",
doi = "10.1007/BF01799376",
language = "English (US)",
volume = "13",
pages = "289--291",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Maternal phenylketonuria pregnancy outcome

T2 - a preliminary report of facial dysmorphology and major malformations

AU - Rouse, B.

AU - Lockhart, Lillian

AU - Matalon, Reuben

AU - Azen, C.

AU - Koch, R.

AU - Hanley, W.

AU - Levy, H.

AU - dela Cruz, F.

AU - Friedman, E.

PY - 1990/5

Y1 - 1990/5

N2 - It is clear from the preliminary data that major malformations, i.e. intrauterine growth retardation, microcephaly and cardiac defects, tend to decrease in frequency as the blood phenylalanine level drops, but not enough to suggest that phenylalanine levels of 600 μmol/L are safe levels. The facial dysmorphic features may be used as a sensitive indicator that blood phenylalanine levels should be below 360 μmol/L. It is hoped that at the end of the collaborative study more data will be available to suggest blood phenylalanine levels which will prevent the deleterious effects of maternal PKU syndrome.

AB - It is clear from the preliminary data that major malformations, i.e. intrauterine growth retardation, microcephaly and cardiac defects, tend to decrease in frequency as the blood phenylalanine level drops, but not enough to suggest that phenylalanine levels of 600 μmol/L are safe levels. The facial dysmorphic features may be used as a sensitive indicator that blood phenylalanine levels should be below 360 μmol/L. It is hoped that at the end of the collaborative study more data will be available to suggest blood phenylalanine levels which will prevent the deleterious effects of maternal PKU syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0025077811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025077811&partnerID=8YFLogxK

U2 - 10.1007/BF01799376

DO - 10.1007/BF01799376

M3 - Article

VL - 13

SP - 289

EP - 291

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 3

ER -